Virginia Kaklamani, MD
Enriched profileProfessor of Medicine (Clinical); Leader, Breast Cancer Program · UT Health San Antonio
Virginia Kaklamani is Professor of Medicine (Clinical); Leader, Breast Cancer Program at UT Health San Antonio. OpenAlex indexes 411 publications with 15,812 citations (h-index 56); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Virginia Kaklamani, MD, is Professor of Medicine (Clinical) at UT Health San Antonio (UT Health San Antonio MD Anderson Cancer Center / Mays Cancer Center), Division of Hematology & Oncology. The public record shows 411 publications with 15,812 citations (h-index 56), centered on Breast Cancer, Ovarian / Gynecologic Cancer. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 21 companies, 3 NIH-funded awards (2016–2025).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Breast Cancer
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Industry payments
Updated 15 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202530 payments$49,925openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202513 payments$12,016openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20256 payments$10,565openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.5%PD-1 inhibitor51.1%Pembrolizumab100%Part B, office-administered≥17 patientsMicrotubule Inhibitor8.1%Docetaxel100%Part B, office-administered≥13 patients+ 7 more classes in this area
Metabolism & gastrointestinal
27.7%Other antiemetics23.4%Fosaprepitant100%Part B, office-administered≥15 patientsSerotonin-3 Receptor Antagonist4.2%Ondansetron hydrochloride52%Palonosetron hcl41%Ondansetron Hcl3%Ondansetron Odt3%Part D + Part B<11 patients+ 1 more class in this area
Sensory organs
4%Corticosteroid4%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
3 NIH research awards on record, funded 2016–2025 per NIH RePORTER. The latest:
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
Article2026 - Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.
International journal of cancer
Clinical Trial2025 - Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.
Breast cancer research and treatment
Article2025 - Breast cancer: The good, the bad, and an important call to effective risk reduction strategies.
CA: a cancer journal for clinicians
Editorial2024
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/virginia-kaklamani-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/virginia-kaklamani-a16a30311
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Virginia-Kaklamani-39315645
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - X / Twitter
x.com/VKaklamani
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/Cjnh7OsOPXS
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
lbbc.org/about-us/medical-advisory-board/virginia-kaklamani-md-dsc
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗ - Other
onclive.com/authors/virginia-kaklamani-md-dsc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Medical degree
National & Kapodistrian University of Athens Medical School, Athens, Greece
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Doctorate of Medical Sciences (DSc)
National & Kapodistrian University of Athens, Athens, Greece
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Master of Science in Clinical Investigation
Northwestern University, Chicago, IL
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Board Certification: American Board of Internal Medicine
Hematology/Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗
Editorial & leadership roles
journal and society appointments- Co-Director
San Antonio Breast Cancer Symposium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Co-Director
Cancer Genetics Program, UT Health San Antonio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Medical Director
Breast Oncology Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗ - Editorial board member
Molecular Cancer Therapeutics (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.silverchair-cdn.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗
Secondary affiliations
appointments beyond the home institution- Medical Advisory Board
Living Beyond Breast Cancer (LBBC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lbbc.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ralph Defronzo, MD
UT Health San Antonio
Andrew Brenner, MD
UT Health San Antonio
Allen Anderson, MD
UT Health San Antonio
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles